Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology

Nature Biotechnology

Volumn 19, Issue 1, 2001, Pages 56-61

  Jenne, Andreas ^a,b   Hartig, Jörg S ^a   Piganeau, Nicolas ^a,c   Tauer, Andreas ^d   Samarsky, Dmitry A ^e   Green, Michael R ^e   Davies, Julian ^f   Famulok, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NascaCell Technologies AG   (Germany)

^c Aventis Gencell   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibiotic libraries; Combinatorial libraries; Hammerhead ribozyme; High throughput screening; RNA drug interaction

Indexed keywords

BISBENZIMIDE; DIMINAZENE ACETURATE; DOXORUBICIN; ENZYME INHIBITOR; FRAMYCETIN; GENTAMICIN; GRAMICIDIN; NEAMINE; NEOMYCIN; PAROMOMYCIN; RIBOZYME; SISOMICIN; TETRACYCLINE DERIVATIVE; TUBERACTINOMYCIN; VIOMYCIN;

ACTINOBACTERIA; ARTICLE; ASSAY; CATALYSIS; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME INHIBITION; FLUORESCENCE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RELIABILITY; RNA BINDING;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CATALYSIS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENVIOMYCIN; KINETICS; NUCLEIC ACID CONFORMATION; RNA, CATALYTIC; STRUCTURE-ACTIVITY RELATIONSHIP;

ACTINOBACTERIA (CLASS); UNCULTURED ACTINOMYCETE;

EID: 0035161011     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/83513     Document Type: Article

References (39)

1. RNA recognition by the human immunodeficiency virus Tat and Rev proteins
2. RNA as a drug target: Chemical, modelling, and evolutionary tools
3. Structure-based and combinatorial search for new RNA-binding drugs
4. RNA as a small-molecule drug target: Doubling the value of genomics
5. Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA
6. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production
7. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism
8. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region
9. Aminoglycoside-RNA interactions
10. Modulation of RNA function by aminoglycoside antibiotics
11. Aminoglycoside binding to the hammerhead ribozyme: A general model for the interaction of cationic antibiotics with RNA
12. Antibiotic interactions with the hammerhead ribozyme: Tetracyclines as a new class of hammerhead inhibitor
13. Neomycin inhibition of the hammerhead ribozyme involves ionic interactions
14. Inhibition of the hammerhead ribozyme by neomycin
15. Designing novel RNA binders
16. Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme
17. RNA as a drug target
18. Hammerhead ribozyme kinetics
19. RNA and the small molecule world
20. Ribosomes. Drugs and the RNA world
21. Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics
22. The crisis in antibiotic resistance
23. Bacterial resistance to aminoglycoside antibiotics
24. Inactivation of antibiotics and the dissemination of resistance genes
25. Real-time characterization of ribozymes by fluorecence resonance energy transfer (FRET)
26. Rapid kinetic characterization of hammerhead ribozymes by real-time monitoring of fluorescence resonance energy transfer (FRET)
27. Non-competitive inhibition of group I intron RNA self-splicing by aminoglycoside antibiotics
28. Antibiotic inhibition of RNA catalysis; neomycin B binds to the catalytic core of the td group I intron displacing essential metal ions
29. Inhibition of RNase P RNA cleavage by aminoglycosides
30. Hairpin ribozyme cleavage catalyzed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions
31. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate
32. Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure
33. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA
34. Controlling gene expression in living cells through small molecule-RNA interactions
35. The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism
36. Berenil [1,3-bis(4′-amidinophenyl)triazene] binding to DNA duplexes and to a RNA duplex: Evidence for both intercalative and minor groove binding properties
37. A small nucleolar RNA: Ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency
38. Ribozymes in the nucleolus
39. The snoRNA box C/D motif directs nucleolar targeting and also couples snoRNA synthesis and localization